Person-Reported and Health Care Utilization Outcomes of Home and Community Based Care Recipients With and Without Alzheimer's Disease and its Related Dementias

患有和不患有阿尔茨海默病及其相关痴呆症的家庭和社区护理接受者的个人报告和医疗保健利用结果

基本信息

  • 批准号:
    10092440
  • 负责人:
  • 金额:
    $ 211.64万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

Project Abstract: More than 5 million Americans live with Alzheimer's disease and related dementias (AD/ADRD), and they receive care from more than 16 million family caregivers. Providing high quality care in the community for people with AD/ADRD is a national priority. Persons with AD/ADRD who are enrolled in Medicaid are eligible to receive home and community-based services (HCBS). HCBS programs vary by state but in general include supportive services (e.g., adult day services and personal care). HCBS are provided by states as an alternative to institutional care and are believed to promote the clients’ independence, health, well-being and help avoid or delay more intensive health care utilization (e.g., nursing home admission). But very little is known about the impact of HCBS for people living with AD/ADRD, including whether person-reported outcomes differ for those with and without AD/ADRD, and whether person- reported HCBS outcomes influence use of health care. To determine whether HCBS improve outcomes that matter to clients, we must first better understand the role of these services from the perspective of care recipients (i.e., person-reported outcomes).Toward that end, we propose to use data from the National Core Indicators-Aging and Disabilities (NCI-AD) Adult Consumer Survey collected between 2017-2020 (n>17,000 HCBS respondents each year), which measure HCBS quality and service outcomes from clients’ perspectives. We also propose to link NCI-AD and Medicare and Medicaid claims for respondents in Minnesota (the only state where this linkage is currently possible) to understand the relationship between person-reported HCBS outcomes and health care use. In response to RFA AG-20-037 we propose the following specific aims: 1. Document trends in the HCBS used and/or desired by clients with and without AD/ADRD. We expect that persons with AD/ADRD will indicate a greater desire to use more HCBS than they currently receive compared to those without AD/ADRD. 2. Determine client and state-level factors that promote person-reported HCBS outcomes among persons with and without AD/ADRD. Hypothesis 2a: Persons with AD/ADRD will have significantly poorer person-reported HCBS outcomes than persons without AD/ADRD. Hypothesis 2b: Greater state investment in HCBS relative to institutional care will be associated with significantly more positive person-reported outcomes for clients both with and without AD/ADRD. 3. Determine the association between health plan-level HCBS person-reported quality and health care use (emergency department, hospitalizations, potentially avoidable hospitalizations, and nursing home admission) for persons with and without AD/ADRD. Clients who receive HCBS from high quality plans (based on person-reported outcomes) will use less health care than their counterparts, and this difference will be larger for clients with AD/ADRD. This study has the potential to yield new evidence both for how HCBS influence important outcomes for persons with AD/ADRD, and for the policy-relevant outcome of health care use.
项目摘要: 超过500万美国人患有阿尔茨海默病和相关痴呆症 (AD/ADRD),他们得到1600多万家庭护理人员的照顾。提供高 在社区为AD/ADRD患者提供高质量的护理是国家的优先事项。人 参加Medicaid的AD/ADRD有资格获得基于家庭和社区的 服务(HCBS)。HCBS计划因州而异,但一般包括支持性服务(例如, 成人日间服务和个人护理)。HCBS由各州提供,作为 机构护理,据信可促进客户的独立性、健康、福祉和 有助于避免或延迟更密集的卫生保健利用(例如,疗养院入院)。但 关于HCBS对AD/ADRD患者的影响知之甚少,包括是否 有和没有AD/ADRD的人报告的结果不同,以及人- 报告的HCBS结果影响卫生保健的使用。确定HCBS是否改善 我们必须首先更好地了解这些服务的作用, 护理接受者的观点(即,个人报告的结果)。为此,我们建议 使用国家核心指标-老龄化和残疾(NCI-AD)成人消费者的数据 2017-2020年期间收集的调查(每年n> 17,000名HCBS受访者), 从客户的角度看HCBS的质量和服务结果。我们还建议将NCI-AD 以及明尼苏达州受访者的医疗保险和医疗补助索赔(这是唯一一个 联系是目前可能的),以了解个人报告的HCBS之间的关系 结果和卫生保健使用。针对RFA AG-20-037,我们提出以下建议 具体目标:1.记录客户使用和/或期望的HCBS趋势, 没有AD/ADRD。我们预计AD/ADRD患者将表示更愿意使用 与没有AD/ADRD的人相比,他们目前接受的六氯代苯更多。2.确定 促进个人报告的HCBS结果的客户和国家层面的因素, 患有和不患有AD/ADRD的人。假设2a:AD/ADRD患者将有 与没有AD/ADRD的人相比,人报告的HCBS结果明显较差。 假设2b:相对于机构护理,国家对HCBS的投资将增加 对于有和没有的客户, AD/ADRD。3.确定健康计划级HCBS个人报告 质量和卫生保健使用(急诊室、住院、潜在 可避免的住院治疗和疗养院入院), AD/ADRD。从高质量计划中获得HCBS的客户(基于个人报告 结果)将比他们的同行使用更少的医疗保健,这种差异将更大, AD/ADRD患者。这项研究有可能产生新的证据,无论是如何HCBS 影响AD/ADRD患者的重要结果,以及 保健用途。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric Jutkowitz其他文献

Eric Jutkowitz的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric Jutkowitz', 18)}}的其他基金

Evaluating the Impact of COVID-19 on Case Management, Health Care Utilization, and Housing Outcomes for HUD-VASH Veterans
评估 COVID-19 对 HUD-VASH 退伍军人的病例管理、医疗保健利用和住房结果的影响
  • 批准号:
    10641154
  • 财政年份:
    2023
  • 资助金额:
    $ 211.64万
  • 项目类别:
Plans4Care: Personalized Dementia Care On-Demand
Plans4Care:按需个性化痴呆症护理
  • 批准号:
    10758864
  • 财政年份:
    2023
  • 资助金额:
    $ 211.64万
  • 项目类别:
Memory Care in Assisted Living: Does it Improve Quality Outcomes?
辅助生活中的记忆护理:它能提高质量结果吗?
  • 批准号:
    10807400
  • 财政年份:
    2023
  • 资助金额:
    $ 211.64万
  • 项目类别:
Did Covid and the Transition to Telehealth Change Person-Reported Outcomes for Home and Community Based Care Recipients With and Without Alzheimer's Disease and its Related Dementias?
新冠疫情和向远程医疗的转变是否改变了患有或不患有阿尔茨海默病及其相关痴呆症的家庭和社区护理接受者的个人报告结果?
  • 批准号:
    10863580
  • 财政年份:
    2020
  • 资助金额:
    $ 211.64万
  • 项目类别:
Microsimulation Modeling to Compare the Effectiveness and Cost-Effectiveness of Nondrug Interventions to Manage Clinical Symptoms in Racially/Ethnically Diverse Persons with Dementia
微观模拟模型比较非药物干预措施管理不同种族/民族痴呆症患者临床症状的有效性和成本效益
  • 批准号:
    10417166
  • 财政年份:
    2019
  • 资助金额:
    $ 211.64万
  • 项目类别:
Microsimulation Modeling to Compare the Effectiveness and Cost-Effectiveness of Nondrug Interventions to Manage Clinical Symptoms in Racially/Ethnically Diverse Persons with Dementia
微观模拟模型比较非药物干预措施管理不同种族/民族痴呆症患者临床症状的有效性和成本效益
  • 批准号:
    10218006
  • 财政年份:
    2019
  • 资助金额:
    $ 211.64万
  • 项目类别:
Informal Resources of Persons Living with Alzheimer's Disease and Related Dementias: Impact on Hospitalizations, Potentially Avoidable Hopsitalizations and Nursing Home Admissions
阿尔茨海默病和相关痴呆症患者的非正式资源:对住院治疗、可能可以避免的住院治疗和疗养院入院的影响
  • 批准号:
    9789802
  • 财政年份:
    2018
  • 资助金额:
    $ 211.64万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 211.64万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了